AGT and Hypertension resistant to conventional therapy: In the KARDIA-1 trial, zilebesiran produced sustained 24 h SBP reductions (~15 mmHg at 6 months) with pronounced nighttime BP lowering, while IONIS-AGT-LR achieved >50% suppression of plasma AGT with favorable BP trends, particularly in resistant hypertension cohorts [79,100].